Patents by Inventor Paul Leslie Ornstein

Paul Leslie Ornstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 6-substituted-3-1,3-benzothiazol-2-one compounds as TARP-gamma 8 dependent AMPA receptor antagonists
    Patent number: 9469632
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: October 18, 2016
    Assignee: Eli Lilly and Company
    Inventors: Kevin Matthew Gardinier, Douglas Linn Gernert, Patric James Hahn, Sean Patrick Hollinshead, Albert Khilevich, Daniel Ray Mayhugh, Paul Leslie Ornstein, Warren Jaye Porter, Jon Kevin Reel, Jeffrey Michael Schkeryantz, Patrick Gianpietro Spinazze, Freddie Craig Stevens, Jeffrey Michael Witkin
  • 6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS
    Publication number: 20150344468
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Application
    Filed: May 21, 2015
    Publication date: December 3, 2015
    Inventors: Kevin Matthew GARDINIER, Douglas Linn GERNERT, Patric James HAHN, Sean Patrick HOLLINSHEAD, Albert KHILEVICH, Daniel Ray MAYHUGH, Paul Leslie ORNSTEIN, Warren Jaye PORTER, Jon Kevin REEL, Jeffrey Michael SCHKERYANTZ, Patrick Gianpietro SPINAZZE, Freddie Craig STEVENS, Jeffrey Michael WITKIN
  • 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
    Patent number: 9056844
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: June 16, 2015
    Assignee: Eli Lilly and Company
    Inventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
  • 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
    Publication number: 20130237573
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 15, 2011
    Publication date: September 12, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
  • Pyrrole and pyrazole derivatives as potentiators of glutamate receptors
    Patent number: 7625932
    Abstract: The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
    Type: Grant
    Filed: August 27, 2004
    Date of Patent: December 1, 2009
    Assignee: Eli Lilly and Company
    Inventors: Pamela Ann Albaugh, Esteban Dominguez-Manzanares, Jian Eric Hong, William Joseph Hornback, Delu Jiang, Paul Leslie Ornstein, Michelle Lee Thompson, Eric George Tromiczak, Zhipei Wu, Hamideh Zarrinmayeh, Dennis Michael Zimmerman, Ana Maria Castano Mansanet, Larry Gene Huffman, William David Miller
  • Excitatory amino acid receptor antagonists
    Patent number: 7601738
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: October 13, 2009
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Paul Leslie Ornstein
  • Melanocortin receptor agonists
    Patent number: 7314879
    Abstract: The present invention relates to melanocortin receptor agonist of the formula (I): which is useful in the treatment for obesity, diabetes, and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: January 1, 2008
    Assignee: Eli Lilly and Company
    Inventors: Ryan Thomas Backer, Caño Ivan Collado, Oscar De Frutos-Garcia, Christopher William Doecke, Matthew Joseph Fisher, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Chaoyu Xie
  • Melanocortin receptor agonists
    Patent number: 7291619
    Abstract: The present invention relates to melanocortin receptor agonists of formula (I), which is useful in the treatment of obesity, diabetes and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: November 6, 2007
    Assignee: Eli Lilly and Company
    Inventors: Christopher Kelly Biggers, Karin Briner, Christopher William Doecke, Matthew Joseph Fisher, Larry Wayne Hertel, Vincent Mancuso, Michael John Martinelli, John Philip Mayer, Paul Leslie Ornstein, Timothy Ivo Richardson, Jikesh Arvind Shah, Qing Shi, Zhipei Wu, Chaoyu Xie
  • Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics
    Patent number: 7247644
    Abstract: Thus, the present invention provides compounds of formula (I) The present invention further provides the use of a compound of formula (I) for the manufacture of a medicament for the treatment of a neurological disorder.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: July 24, 2007
    Assignee: Eli Lilly and Company
    Inventor: Paul Leslie Ornstein
  • Excitatory amino acid receptor antagonists
    Patent number: 7205313
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Melanocortin receptor agonists
    Patent number: 7169777
    Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: January 30, 2007
    Assignee: Eli Lilly and Company
    Inventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Caño, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie
  • Selective iGluRreceptor antagonists
    Patent number: 7157582
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: January 2, 2007
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Excitatory amino acid receptor antagonists
    Patent number: 6953805
    Abstract: The present invention provides novel compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising an effective amount of a compound of Formula I or Formula II in combination with a suitable carrier, diluent, or excipient, and methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: October 11, 2005
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Kevin John Hudziak, Brian Michael Mathes, Paul Leslie Ornstein
  • Excitatory amino acid receptor antagonists
    Patent number: 6855725
    Abstract: The present invention provides compounds of Formula I or Formula II, or the pharmaceutically acceptable salts or prodrugs thereof, pharmaceutical compositions comprising compounds or Formula I or Formula II, and methods for treating neurological disorders and neurodegenerative diseases, particularly migraine.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: February 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Sandra Ann Filla, Paul Leslie Ornstein
  • Selective iGluR5 receptor antagonists
    Patent number: 6855823
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: February 15, 2005
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Selective iGluR5 receptor antagonists
    Publication number: 20040192722
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR5 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 receptor antagonists.
    Type: Application
    Filed: April 9, 2004
    Publication date: September 30, 2004
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Sulphonamide derivatives
    Publication number: 20040157842
    Abstract: The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.
    Type: Application
    Filed: February 6, 2004
    Publication date: August 12, 2004
    Inventors: Macklin Brian Arnold, Paul Leslie Ornstein, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
  • Excitatory amino acid receptor antagonists
    Publication number: 20040138254
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Mark Alan Winter, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Selective iGluR5 receptor antagonists for the treatment of neurological disorders
    Patent number: 6759418
    Abstract: The present invention provides a method of treating or preventing migraine comprising administering to a patient in need thereof an effective amount of a selective iGluR5 receptor antagonist. The present invention further provides novel compounds functional as selective iGluR4 receptor antagonists as well as compositions and formulations comprising said selective iGluR5 rec antagonists.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: July 6, 2004
    Assignee: Eli Lilly and Company
    Inventors: Sandra Ann Filla, Paul Leslie Ornstein
  • Melanocortin receptor agonists
    Publication number: 20040116699
    Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction 1
    Type: Application
    Filed: July 11, 2003
    Publication date: June 17, 2004
    Inventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Cano, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie